Physician profile
Brian Peck
NPI 1629036868
$1,590.89
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $544 · 2021: $504 · 2022: $168.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $380.52 | 2019-2022 | |
| Abbvie INC. | $293.39 | 2020-2021 | |
| Janssen Biotech, INC. | $280.28 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $131.30 | 2020-2022 | |
| Glaxosmithkline, LLC. | $97.11 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $63.59 | 2020-2022 | |
| Genentech USA, INC. | $49.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.56 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $37.51 | 2021-2022 | |
| Redhill Biopharma INC. | $36.35 | 2020-2021 | |
| Ucb, INC. | $35.33 | 2020-2021 | |
| Medexus Pharma, INC. | $27.24 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.61 | 2022 | |
| Lilly USA, LLC | $21.53 | 2020 | |
| Depuy Synthes Sales INC. | $20.34 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $17.87 | 2020 | |
| Assertio Therapeutics, INC. | $17.14 | 2020 | |
| Pfizer INC. | $11.34 | 2019 | |
| Organon LLC | $10.98 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Peck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.